EG25829A - Novel treatment - Google Patents
Novel treatmentInfo
- Publication number
- EG25829A EG25829A EG2001080869A EG2001080869A EG25829A EG 25829 A EG25829 A EG 25829A EG 2001080869 A EG2001080869 A EG 2001080869A EG 2001080869 A EG2001080869 A EG 2001080869A EG 25829 A EG25829 A EG 25829A
- Authority
- EG
- Egypt
- Prior art keywords
- novel treatment
- novel
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0019728.5A GB0019728D0 (en) | 2000-08-10 | 2000-08-10 | Novel treatment |
GB0101334A GB0101334D0 (en) | 2001-01-18 | 2001-01-18 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
EG25829A true EG25829A (en) | 2012-09-02 |
Family
ID=26244821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EG2001080869A EG25829A (en) | 2000-08-10 | 2001-08-08 | Novel treatment |
Country Status (36)
Country | Link |
---|---|
US (3) | US20030235590A1 (ko) |
EP (2) | EP1307473B1 (ko) |
JP (2) | JP2004505992A (ko) |
KR (1) | KR100804922B1 (ko) |
CN (1) | CN1468256B (ko) |
AP (1) | AP2003002734A0 (ko) |
AR (1) | AR030325A1 (ko) |
AT (2) | ATE313558T1 (ko) |
AU (2) | AU8207301A (ko) |
BG (1) | BG66038B1 (ko) |
BR (1) | BRPI0113155C1 (ko) |
CA (2) | CA2427475C (ko) |
CY (2) | CY1106310T1 (ko) |
CZ (1) | CZ303217B6 (ko) |
DE (2) | DE60136400D1 (ko) |
DK (2) | DK1307473T3 (ko) |
DZ (1) | DZ3470A1 (ko) |
EA (1) | EA006433B1 (ko) |
EG (1) | EG25829A (ko) |
ES (2) | ES2254464T3 (ko) |
HK (1) | HK1056884A1 (ko) |
HU (1) | HU228932B1 (ko) |
IL (2) | IL154301A0 (ko) |
MX (1) | MXPA03001235A (ko) |
MY (1) | MY128999A (ko) |
NO (1) | NO20030635L (ko) |
NZ (1) | NZ524012A (ko) |
OA (1) | OA12361A (ko) |
PE (1) | PE20020287A1 (ko) |
PL (1) | PL204736B1 (ko) |
PT (1) | PT1666487E (ko) |
SI (2) | SI1307473T1 (ko) |
SK (2) | SK288079B6 (ko) |
UA (1) | UA79735C2 (ko) |
UY (1) | UY26882A1 (ko) |
WO (1) | WO2002012287A1 (ko) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA79735C2 (uk) * | 2000-08-10 | 2007-07-25 | Глаксосмітклайн Байолоджікалз С.А. | Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах |
GB0202901D0 (en) * | 2002-02-07 | 2002-03-27 | Glaxosmithkline Biolog Sa | Novel vaccine |
BRPI0613025A2 (pt) * | 2005-07-11 | 2010-12-14 | Globeimmune Inc | composiÇço para reduzir a resistÊncia a um agente, mÉtodo para a preparaÇço de um veÍculo de levedura e uso da composiÇço |
EA014314B1 (ru) * | 2005-08-02 | 2010-10-29 | Новартис Вэксинес Энд Дайэгностикс Срл | Пониженная интерференция между маслосодержащими адъювантами и антигенами, содержащими поверхностно-активные вещества |
GB0522765D0 (en) * | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
GB0612142D0 (en) | 2006-06-20 | 2006-08-02 | Secr Defence | Spreading modulation spectrum control |
EP2066344B2 (en) | 2006-09-07 | 2016-06-29 | GlaxoSmithKline Biologicals S.A. | Inactivated Poliovirus combination vaccine |
EA201490303A1 (ru) | 2007-05-02 | 2014-05-30 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина |
WO2009057699A1 (ja) * | 2007-10-30 | 2009-05-07 | Kyocera Corporation | 弾性波装置 |
US8250102B2 (en) * | 2008-03-14 | 2012-08-21 | Microsoft Corporation | Remote storage and management of binary object data |
KR100959145B1 (ko) | 2008-03-21 | 2010-05-25 | 중앙대학교 산학협력단 | 인유두종바이러스 바이러스 유사 입자의 생산 및 정제 방법 |
CA2725329C (en) * | 2008-05-23 | 2013-10-01 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
EA020617B1 (ru) * | 2009-05-27 | 2014-12-30 | Глаксосмитклайн Байолоджикалс С.А. | Конструкции casb7439 |
PT2705365T (pt) * | 2011-01-14 | 2016-09-19 | Hal Allergy Holding B V | Imunoensaio para determinação direta do teor de antigénio de produtos compreendendo partículas de antigénio acoplado a adjuvante |
GB201105981D0 (en) | 2011-04-08 | 2011-05-18 | Glaxosmithkline Biolog Sa | Novel process |
CN106222129A (zh) * | 2016-07-29 | 2016-12-14 | 广东东阳光药业有限公司 | 一种提高抗体纯度的细胞培养基和培养方法 |
CA3070039A1 (en) | 2017-07-18 | 2019-01-24 | Serum Institute Of India Pvt Ltd. | An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof |
GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
GB201721068D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B immunisation regimen and compositions |
CA3132601A1 (en) | 2019-03-05 | 2020-09-10 | Glaxosmithkline Biologicals Sa | Hepatitis b immunisation regimen and compositions |
AU2020403296A1 (en) * | 2019-12-13 | 2022-07-07 | Grand Theravac Life Science (Nanjing) Co., Ltd. | Immunostimulatory composition and use thereof |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1030777A (en) * | 1963-12-06 | 1966-05-25 | Ciba Ltd | Method of preparing a vaccine against trypanosoma cruzi infections |
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
US4720385A (en) * | 1983-03-29 | 1988-01-19 | Miles Laboratories, Inc. | Protein compositions substantially free from infectious agents |
JPS6013718A (ja) | 1983-07-05 | 1985-01-24 | Chemo Sero Therapeut Res Inst | B型肝炎ワクチン |
KR850001534A (ko) | 1983-08-22 | 1985-03-30 | 제임스 에프. 나우톤 | 형질전환된 효모로 부터 유도된 면역원성 HBsAg |
US4683294A (en) | 1985-04-03 | 1987-07-28 | Smith Kline Rit, S.A. | Process for the extraction and purification of proteins from culture media producing them |
FI861417A0 (fi) | 1985-04-15 | 1986-04-01 | Endotronics Inc | Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav. |
US4649192A (en) * | 1985-05-30 | 1987-03-10 | Smith Kline-Rit | Method for the isolation and purification of hepatitis B surface antigen using polysorbate |
US4895800A (en) | 1985-11-26 | 1990-01-23 | Phillips Petroleum Company | Yeast production of hepatitis B surface antigen |
EP0278940A3 (en) | 1987-01-30 | 1988-12-07 | Smithkline Biologicals S.A. | Hepatitis b virus surface antigens and hybrid antigens containing them |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
EP1088830A3 (en) | 1987-06-22 | 2004-04-07 | Medeva Holdings B.V. | Hepatitis b surface antigen particles |
DE3789866T2 (de) | 1987-07-17 | 1994-09-22 | Rhein Biotech Proz & Prod Gmbh | DNA-Moleküle, die für FMDH-Kontrollabschnitte und Strukturgene für ein Protein mit FMDH-Aktivität kodieren, sowie deren Anwendung. |
EP0314240A3 (en) * | 1987-10-26 | 1990-03-28 | Merck & Co. Inc. | Process for purifying recombinant hepatitis antigens |
JPH085804B2 (ja) | 1988-04-28 | 1996-01-24 | 財団法人化学及血清療法研究所 | A型及びb型肝炎混合アジュバントワクチン |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5242812A (en) * | 1989-02-07 | 1993-09-07 | Bio-Technology General Corp. | Method for production and purification of hepatitis B vaccine |
US5274081A (en) * | 1989-09-20 | 1993-12-28 | Immuno A.G. | Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen |
GB9007024D0 (en) | 1990-03-29 | 1990-05-30 | Imperial College | Novel vaccine |
WO1992011291A1 (en) | 1990-12-20 | 1992-07-09 | Smithkline Beecham Biologicals (S.A.) | Vaccines based on hepatitis b surface antigen |
JP3026029B2 (ja) | 1991-04-26 | 2000-03-27 | 財団法人阪大微生物病研究会 | 組換え水痘ウイルスとその作製法 |
AU657168B2 (en) | 1991-09-18 | 1995-03-02 | Amgen, Inc. | Hepatitis B vaccine with bile salt adjuvant |
US6620414B2 (en) * | 1992-03-27 | 2003-09-16 | Smithkline Beecham Biologicals (S.A.) | Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A |
HU219808B (hu) | 1992-06-25 | 2001-08-28 | Smithkline Beecham Biologicals S.A. | Adjuvánst tartalmazó vakcinakompozíció és eljárás annak előállítására |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
CA2194761C (en) | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
DE69535530D1 (de) * | 1994-10-24 | 2007-08-16 | Ophidian Pharm Inc | Impfstoff und Antitoxine zur Behandlung und Vorbeugung von C. Difficile Krankheiten |
KR960023066A (ko) * | 1994-12-10 | 1996-07-18 | 성재갑 | 전에스 (s) 2 펩티드 함유 비 (b) 형 간염 표면항원의 정제 방법 |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
BR9908599A (pt) * | 1998-03-09 | 2000-11-14 | Smithkline Beecham Biolog | Composições combinadas de vacina |
JP4620251B2 (ja) | 1998-08-10 | 2011-01-26 | アンチジェニックス・インコーポレイテッド | Cpgおよびサポニンアジュバントの組成物並びにその方法 |
JP2002532116A (ja) * | 1998-12-23 | 2002-10-02 | メルク エンド カムパニー インコーポレーテッド | 改良された組換えb型肝炎表面抗原 |
UA79735C2 (uk) * | 2000-08-10 | 2007-07-25 | Глаксосмітклайн Байолоджікалз С.А. | Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах |
-
2001
- 2001-07-08 UA UA2003021025A patent/UA79735C2/uk unknown
- 2001-08-07 EP EP01960630A patent/EP1307473B1/en not_active Expired - Lifetime
- 2001-08-07 JP JP2002518258A patent/JP2004505992A/ja active Pending
- 2001-08-07 PT PT05077471T patent/PT1666487E/pt unknown
- 2001-08-07 DK DK01960630T patent/DK1307473T3/da active
- 2001-08-07 DE DE60136400T patent/DE60136400D1/de not_active Expired - Lifetime
- 2001-08-07 EA EA200300129A patent/EA006433B1/ru not_active IP Right Cessation
- 2001-08-07 AU AU8207301A patent/AU8207301A/xx active Pending
- 2001-08-07 CA CA2427475A patent/CA2427475C/en not_active Expired - Lifetime
- 2001-08-07 AP APAP/P/2003/002734A patent/AP2003002734A0/en unknown
- 2001-08-07 NZ NZ524012A patent/NZ524012A/en unknown
- 2001-08-07 DZ DZ013470A patent/DZ3470A1/fr active
- 2001-08-07 CZ CZ20030385A patent/CZ303217B6/cs not_active IP Right Cessation
- 2001-08-07 WO PCT/EP2001/009100 patent/WO2002012287A1/en active IP Right Grant
- 2001-08-07 PL PL362322A patent/PL204736B1/pl unknown
- 2001-08-07 ES ES01960630T patent/ES2254464T3/es not_active Expired - Lifetime
- 2001-08-07 OA OA1200300038A patent/OA12361A/en unknown
- 2001-08-07 HU HU0302951A patent/HU228932B1/hu not_active IP Right Cessation
- 2001-08-07 EP EP05077471A patent/EP1666487B1/en not_active Expired - Lifetime
- 2001-08-07 DE DE60116107T patent/DE60116107T2/de not_active Expired - Lifetime
- 2001-08-07 US US10/344,211 patent/US20030235590A1/en not_active Abandoned
- 2001-08-07 CN CN018169988A patent/CN1468256B/zh not_active Expired - Lifetime
- 2001-08-07 AT AT01960630T patent/ATE313558T1/de active
- 2001-08-07 SI SI200130489T patent/SI1307473T1/sl unknown
- 2001-08-07 AT AT05077471T patent/ATE412665T1/de active
- 2001-08-07 MX MXPA03001235A patent/MXPA03001235A/es active IP Right Grant
- 2001-08-07 DK DK05077471T patent/DK1666487T3/da active
- 2001-08-07 IL IL15430101A patent/IL154301A0/xx unknown
- 2001-08-07 SK SK50032-2012A patent/SK288079B6/sk not_active IP Right Cessation
- 2001-08-07 CA CA2740282A patent/CA2740282A1/en not_active Abandoned
- 2001-08-07 KR KR1020037001933A patent/KR100804922B1/ko active IP Right Grant
- 2001-08-07 ES ES05077471T patent/ES2314555T3/es not_active Expired - Lifetime
- 2001-08-07 SK SK169-2003A patent/SK288069B6/sk not_active IP Right Cessation
- 2001-08-07 SI SI200130884T patent/SI1666487T1/sl unknown
- 2001-08-07 AU AU2001282073A patent/AU2001282073B2/en not_active Expired
- 2001-08-07 BR BRPI0113155A patent/BRPI0113155C1/pt not_active IP Right Cessation
- 2001-08-08 EG EG2001080869A patent/EG25829A/xx active
- 2001-08-08 AR ARP010103790A patent/AR030325A1/es active IP Right Grant
- 2001-08-08 PE PE2001000786A patent/PE20020287A1/es not_active Application Discontinuation
- 2001-08-10 UY UY26882A patent/UY26882A1/es not_active Application Discontinuation
- 2001-08-10 MY MYPI20013779A patent/MY128999A/en unknown
-
2003
- 2003-02-05 IL IL154301A patent/IL154301A/en active IP Right Grant
- 2003-02-07 NO NO20030635A patent/NO20030635L/no unknown
- 2003-02-07 BG BG107545A patent/BG66038B1/bg active Active
- 2003-10-14 HK HK03107371A patent/HK1056884A1/xx not_active IP Right Cessation
-
2005
- 2005-11-03 US US11/266,565 patent/US20060159705A1/en not_active Abandoned
-
2006
- 2006-03-07 CY CY20061100311T patent/CY1106310T1/el unknown
-
2008
- 2008-12-10 CY CY20081101440T patent/CY1108789T1/el unknown
- 2008-12-23 US US12/342,220 patent/US8624004B2/en not_active Expired - Lifetime
-
2012
- 2012-08-16 JP JP2012180462A patent/JP5559847B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0028264D0 (en) | Well treatment | |
GB0028269D0 (en) | Well treatment | |
EP1296699A4 (en) | THERAPEUTIC AGENTS - III | |
HK1050007A1 (en) | Novel biarylcarboxamides | |
GB0112343D0 (en) | Well treatment | |
AU8860401A (en) | Novel guanidinobenzamides | |
GB0028429D0 (en) | Therapy | |
EG25829A (en) | Novel treatment | |
PL362855A1 (en) | Improved treatment | |
GB0030845D0 (en) | Novel treatment | |
GB9925136D0 (en) | Novel treatment | |
PL349347A1 (en) | Novel treatment | |
AU1217102A (en) | Novel arylalkane-sulfonamides | |
AU8197001A (en) | Novel arylethene-sulfonamides | |
GB0029125D0 (en) | Novel treatment | |
GB0103031D0 (en) | Novel treatment | |
GB0031321D0 (en) | Treatment | |
GB0019728D0 (en) | Novel treatment | |
GB0022992D0 (en) | Novel vompounds | |
GB0006974D0 (en) | Novel treatment | |
GB0029122D0 (en) | Novel treatment | |
GB0029127D0 (en) | Novel treatment | |
GB0012760D0 (en) | Treatment | |
GB0017495D0 (en) | Treatment | |
GB0006415D0 (en) | Treatment |